|
pubmed:abstractText |
Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials.
|
|
pubmed:affiliation |
Amgen, Inc, One Amgen Center Dr, MS 38-2-B, Thousand Oaks, CA 91320-1799, USA. ramado@amgen.com
|
